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1. Introduction 
Immunodeficiency (or immune deficiency) is a state in which the immune system's ability to 
fight infectious disease is compromised or entirely absent. Most cases of immunodeficiency 
are acquired (secondary) but some people are born with defects in their immune system 
(Primary) immunodeficiency.  
The following conditions and diseases that are associated with primary immunodeficiency 
disorder include, Combined variable immunodeficiency disease, Ataxia-telangiectasia, 
Chediak-Higashi syndrome, Complement deficiencies, DiGeorge syndrome, 
Hypogammaglobulinemia, Job syndrome, Leukocyte adhesion defects, Bruton disease, 
Congenital agammaglobulinemia, Selective deficiency of IgA, Wiscott-Aldrich syndrome etc 
As for acquired immunodeficiency, in 2006, UNAIDS and the World Health Organization 
estimated that approximately 39.5 million people were living with HIV. That year alone, 
there were 4.3 million new infections, with the majority occurring in sub-Saharan Africa. 
HIV targets T cells, and in particular, T helper cells, which are critical to fighting infections 
caused by fungi and parasites. This is why people with advanced, untreated AIDS develop 
unusual infections such as Pneumocystis carinii pneumonia and Toxoplasmosis gondii.  
Since transplanted organs such as kidneys, hearts, livers, and lungs are foreign bodies, 
recipients' immune systems must be permanently suppressed to prevent them from 
attacking and destroying the organs. More than 19,000 transplants are performed in the 
United States each year. Each month, approximately 3,700 people are added to the U.S. 
national transplant waiting list, and each day, 77 people receive organ transplants. The 
breakthrough in transplant technology occurred in 1983 when cyclosporine, a powerful 
immunosuppressive drug, became licensed. However, even with cyclosporine, transplanted 
organs typically only last around 10 years before needing to be replaced. Research efforts to 
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induce bodies to tolerate transplanted organs without using immunosuppressive drugs are 
ongoing. But until a breakthrough in understanding immunologic tolerance or a way to 
grow replacement organs occurs, newly immunocompromised organ-transplant recipients 
will occur each year. 
In addition, cancer chemotherapies typically cause immunosuppression. Since cancer cells 
are cells that multiply uncontrollably, the goal of cancer therapy is to kill them without 
killing too many normal cells. Unfortunately, the cells involved in immunity are 
frequently adversely affected by chemotherapy, thus rendering the patient vulnerable to 
infections. 
Autoimmune disorders are typically treated with immunosuppressive drugs such as 
corticosteroids, 6-mercaptopurine, and azathioprine to keep the immune system from 
attacking the body. For example, Crohn's disease is an autoimmune disease in which the 
immune system attacks the body's gastrointestinal system, causing intense pain, bleeding, 
and obstructions. Another treatment is infliximab, which stops the body’s inflammatory 
response. But these treatments only alleviate pain and suffering, they don't cure the 
underlying immune disorder. 
Also splenectomy, diabetes mellitus, cancer, increasing age, chronic diseases and strenuous 
exercise had been associated with various degrees of impairment in immune functions 
The immune System`s primary function is to fight off infection. When the immune system is 
suppressed or dysfunctional the ability to combat infection is reduced. A person who has an 
immunodeficiency of any kind is said to be immunocompromised. These 
immunocompromised patients are more vulnerable to infections including infection with 
organisms that don’t normally cause disease. In addition, they are more likely to develop 
severe and sometimes life-threatening illness following infection. 
Many patients admitted into the Medical Unit especially Intensive Care Unit (ICU) have 
varying degrees of immunosuppression. In some, immunosuppression is easily apparent, 
especially when caused directly by underlying disease (such as haematological malignancy) 
or treatment (such as drugs used to prevent organ rejection or as a side effect of cancer 
chemotherapy). In others, immunosuppression is less apparent and is induced by the 
underlying disease, for example following traumatic injury or sepsis, or as a response to 
therapies provided during intensive care such as steroids. 
Immunosuppression itself does not cause pathology but does leave the patient prone to 
infection and other disease conditions. There is no good clinical test to measure the degree 
of immunosuppression; the clinician must simply maintain a high index of suspicion. The 
consequences of immune suppression in most patients highlight the importance of infection 
prevention and control, as well as surveillance measures to ensure that appropriate 
treatment is implemented safely and quickly. Thus there is need to understand the pattern 
of clinical presentations of patients with immune dysfunction to avoid delay in making 
diagnosis and hence intervention. 
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Immunocompromised patients are prone to various infectious and non infectious disorders. 
The infectious disease is the commonest presentations of these patients because of the 
weakening of the patient’s immune state. The severity of the infection depends on the 
degree of the immunosuppression. Some organs like respiratory pathways are more liable to 
infections in these patients for obvious anatomical reasons; however all organs are at risk of 
developing infection.  
Also there are various non infectious manifestation in patients with immunosuppression. 
These may be directly or indirectly related to the degree of immune suppression in the 
patient. Patients have presented with various degrees of impaired kidney function, liver 
disease, cardiorespiratory dysfunction, psychosocial, dermatological and neurological 
disorders that are not directly related to infections.  
Immunocompromised patients also can present with features not directly related to 
immunosupression. For example obesity in patients on steroid therapy, and hepatic disease 
associated with severe combined immunodeffiency disease. 
Clinical presentations in immunocompromised differs among patients. The presentations 
are determined by the severity of the immunosupression, the severity of the infection and 
other comorbid condition. Furthermore the organ involved and the type of the associated 
clinical state play important role in determining the presentation of the patient. There are 
many uncommon presentations that have been reported in these patients. However poor 
response to treatment of infection, incomplete recovery from illness, certain types of 
infections and malignancies are common presentations seen in immunocompromised 
patients.  
The clinical setting is extremely important in recognizing immunosuppression. Immune 
dysfunction induced by therapeutic intervention will be evident from the history, but 
immune impairment due to underlying disease may be more difficult to recognize. Inherited 
immune deficiencies often have characteristic patterns of disease distribution and may be 
associated with other clinical abnormalities (such as cardiac anomalies). 
The various organs/systems in the body have differing impact by the resultant effect of 
immunosuppression. This results from either the direct impact of the immunosupression or 
diseases resulting from the immunosupression.  
These manifestations will be discussed according to the impact on various systems and 
organs..  
2. Gastrointestinal tract in immunocompromised 
The primary function of the gastrointestinal tract is digestive, absorption and assimilation of 
nutrients. It has the largest surface area among all organs. With such large surface area and 
its close proximity to the external environment it necessitates that it evolved a large 
compliment of both innate and acquired immune mechanism. The gastrointestinal 
associated lymphoid tissue constitutes the largest immune compartment in the body. It is 
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estimated that the GIT contains about 60% of the total body lymphocyte. The immune cells 
in the GIT are organized into distinct anatomic and functional sub compartments.. 
The gastrointestinal tract associated lymphoid tissue, can be divided into three sectors. The 
first is represented by the pharyngeal tonsils, the appendix, and the large aggregates of 
nodules known as Peyer patches located at intervals throughout the small intestine. The 
second sector includes the lymphocytes and plasma cells that populate the basement 
membrane (lamina propria) of the small intestine, the area of loose connective tissue above 
the supporting tissue of the mucosal lining extending into the villi. The third sector 
comprises lymphocytes that lie between the epithelial cells in the mucosa. The interaction 
between these cells of the lymphatic system and the threatening agent is the basis of defense 
in the gastrointestinal tract. The gastrointestinal tract also posses other protective measures 
which include tight epithelial junctions, the digestive enzymes, the acidic gastric fluid, the 
lysozyme and the high flow of the gastrointestinal fluid.  
However the gastrointestinal tract is particularly at risk of infectious and non infectious 
injuries because of the following reasons – because of their close proximity to the external 
environment and continuous exposure to myriad of food and other infectious and non 
infectious antigens, the mucosa is maintained in physiologic inflammatory state 
characterized by presence of proinflammatory cytokines, marked expression of CCR5 and 
CXCR4 chemokine receptor that promotes HIV entry into the mucosa cells. 
In immunocompromised patients the normal defenses are disrupted, leading to a wide 
range of clinical and pathogenic consequences. This usually leads to various disease 
conditions that can be classified into one of several general categories: infections, mucosal 
injury and ulceration, biliary tract diseases, diverticular disease, pancreatitis, and 
malignancy  
The infections may be bacterial, viral, fungal, or parasitic and may infect one or more gut 
segments between the mouth and anus. The viral infections that had been reported in these 
patients include cytomegalovirus, herpes simplex, human papilloma virus, ebstein barr 
virus and rota virus. The bacterial infections include cloctridium dificile, salmonella spp, 
shigella spp, H. pylori, eiserichia coli, campylobacter spp, Yersinia enterocolitica, 
mycobacterium tuberculosis, mycobacterium avium intracellurale complex. The parasitic 
infections include cryptosporidium, microsporidium, entamoeba histolytica, giardia lamblia, 
Strongyloides stercoralis. The fungal infections include histoplasma capsulatum, candida albicans, 
candida tropicalis, mucormyces spp. The gastrointestinal infections have varying presentations but 
the commonest presentation is diarrhea.  
Mucosal injuries and ulceration of the gastrointestinal tract has been reported in patients with 
immunodeficiency. Many factors had been associated with ulcer formation and propagation in these 
patients. Some of these factors include stress, impairment of native cytoprotection of the 
gastrointestinal mucosa, drugs and infections especially helicobacter pylori. Complications that had 
resulted from gastrointestinal mucosa injury and ulceration include perforation, penetration, 
peritonitis and gastrointestinal bleeding. 
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Diverticular disease had been reported in immunocompromised patients especially in post transplant 
patients on immunosuppressive therapy. The clinical presentation varies from asymptomatic to 
peritonitis. Complicated diverticulitis which was reported in 1.1% of renal transplant patients can 
presents as intestinal perforation, abscess, phlegmon or fistula. 
Acute pancreatitis in immunocompromised patients are not common. It has been associated with 
alcohol ingestion, billiary stones, malignancy, hepatitis B and cytomegalovirus infection. Acute 
pancreatitis markedly increase the morbidity and mortality associated with immunodeficiency. The 
clinical presentation is usually atypical. 
There is increase in prevalence of both common and uncommon gastrointestinal malignancies in 
patients with immune deficiency. Decreased immune surveillance, continuous mucosa 
inflammation, gastrointestinal infections, ingestion of carcinogens including medications are some 
of the factors suspected to be responsible for the heightened prevalence of malignancy in these 
patients. Also cigarette smoking, sclerosing cholangitis, crohns syndrome and splenectomy had 
been reported as risk factor for the development of gastrointestinal malignancy in these patients. 
The gastrointestinal malignancies that have been associated with immunosuppression include 
Kaposi sarcoma, colorectal carcinoma, post transplant lymphoproliferative lymphoma, gastric 
mucosa associated lymphoma. The malignancies are initially asymptomatic however acute abdomen 
from perforation or obstruction and gastrointestinal bleeding are the usual though late 
presentations. 
The commonly experienced gastrointestinal (digestive) complications; include oral lesions, 
esophageal lesions, diarrhea, and anorectal diseases (disease that affects the anus and/or 
rectum). The oral lesions are aphthous ulcer, oral thrush (candidiasis), oral wart, oral hairy 
leukoplakia, Kaposi sarcoma. 
The oesophageal lesions include oesophageal candidiasis, oesopheal herpes simplex, 
cytomegalovirus, aphthous ulcer, malignancy, and reflux oesophagitis manifesting as 
dysphagia, odynophagia, and sensation of food sticking in the throat.  
The anorectal lesions which are usually seen in immunocompromised patients with AIDS 
include herpes simplex infection, gonorhoea, syphilis, anal wart(condylomata) and 
Chlamydia.  
Diarhoea is a common clinical presentation in immunocompromised patients independent 
of the cause. This has been attributed to gastrointestinal infections, malabsorption, 
medications etc. 
3. Hepato billiary system in immunocompromised  
The hepatobilliary system is usually considered part of the digestive system however they 
have both digestive and non digestive functions. The liver acts as a detoxifier by processing 
potentially harmful agents into safe chemicals. It is also responsible for metabolism of 
glucose, fat and protein. It manufactures and controls the release of bile.  
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The bile plays an important role in breaking down of fats, the source of cellular energy. It is 
necessary for the absorption of many vitamins and other fat related substances. It also 
participates in the excretion of many product of metabolism including bilirubin, bile acid 
and medications. 
The hepatobilliary system receives dual blood supply, from the portal and systemic 
circulation. Hence in immunocompromised patient the hepatobilliary system is exposed to 
many infectious and non infectious antigens. This predisposes the patient to many disease 
conditions relating/affecting the system.  
Immunodeficiency states resulting from AIDS, cytotoxic chemotherapy, radiation, organ 
transplantation and common variable immunodeficiency disorders have been associated 
with hepatobilliary disease. These disorders that have been reported in 
immunocompromised patients include infectious hepatitis, granulomatous hepatitis, 
alcoholic liver disease, cholangiopathy, hepatocellular carcinoma, schistosomiasis, 
haemangioma and hepatic adenoma. Nodular regenerative hyperplasia of the liver has also 
been reported in patients with combined variable immunodeficiency syndrome. 
There are various clinical manifestations relating to this system in these patients. In a study 
of patients with common variable immunodeficiency syndrome with nodular regenerative 
hyperplasia 39% of the patients were asymptomatic but had deranged liver functions, 46% 
had jaundice, 46% had hepatomegaly, 23% had pruritus, 15% had ascitis, 15% had 
oesophageal varices. Also jaundice and hepatomegaly is a common presentation in 
immunocompromised patients resulting from opportunistic and conventional infections of 
either hepatobilliary or other systems. Other manifestations include portal hypertension, 
cirrhosis, primary and secondary malignancies of the liver and billiary tree, and hepatic 
failure. 
4. Respiratory system in immunocompromised 
The immune system in the airways consists of both innate and specific immunity. Innate 
immunity consists of mechanical defenses, antimicrobial molecules generated in the 
airways, and phagocytic defenses provided by the resident alveolar macrophages and the 
polymorphonuclear leukocytes (PMNs) that are recruited into the lung in response to 
infection. The specific immunity are usually initiated by the dendritic cell that act as the 
antigen presenting cell. They migrate to the regional lymphoid tissue to initiate the primary 
response with generation of memory B and T cells.  
This sophisticated immune defense system effectively protects the host from infections and 
other immunodeficiency related diseases of the respiratory tract. However this function is 
impaired in immunocompromised individuals thus exposing them to many diseases of the 
airways.  
Patients with compromised immune function suffer from a wide variety of infectious and 
non infectious lung insults. Infections are the most common cause of both acute and chronic 
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lung diseases in immunocompromised patients however noninfectious diseases are not 
uncommon.  
Pulmonary infections decisively contribute to morbidity and mortality in 
immunocompromised patients. The prevalence of both the common infections implicated in 
community acquired pneumonia and some uncommon infections including opportunistic 
infections are increased in immunocompromised patients. Among the infections 
encountered are streptococcus pneumoniae, klebsiella pneumonia, haemophilus influenza, 
pseudomonas aeruginosa, actinobacter spp, fusobacterium nucleatum, bacteroids 
melaninogenicus, bacteroids fragilis, mycobacterium tuberculi, mycobacterium avium 
intracellurale, pneumocystis carinii (jirovecii), norcadia spp, coccidomyces spp, aspergilus 
spp, Rhodococcus equi etc. The infections usually present as pneumonia, suppurative lung 
disease, interstitial lung disease and obstructive lung diseases  
The spectrum of noninfectious lung injury and response in the immunosuppressed host 
includes interstitial edema, interstitial fibrosis, diffuse idiopathic pneumonia, acute 
respiratory distress syndrome, obliterative bronchiolitis, alveolar hemorrhage, pulmonary 
embolism, radiation pneumonitis, drug toxicity, progression or recurrence of neoplastic 
disorders, chemotherapy, transfusion and transplant related lung injuries. The clinical 
manifestations of various non infectious complications in immunocompromised patients are 
non specific and may mimic infections. 
Clinical approach to respiratory tract diseases in immunocompromised patients are 
classified into five categories. The first situation is defined by a slow progression of the 
disease, the absence of fever (or mild fever), and diffuse opacities. Pulmonary oedema, 
pulmonary localisation of the underlying disease, or toxic treatment induced pneumonitis 
are usually the cause. Non-specific pneumonitis may also be responsible, particularly in 
bone marrow transplant recipients.  
The second situation, defined by a rapid progression of the condition, fever, and diffuse 
opacities, usually indicates an opportunistic pneumonia but, in a few cases, a 
hypersensitivity drug induced pneumonitis (for example, to methotrexate) or a localisation 
of the underlying disease—for example, in cases of vasculitis or collagen vascular disease—
may be the cause. In the absence of new extrapulmonary symptoms, Pneumocystis carinii 
must be considered. In contrast, the presence of new extrapulmonary symptoms or signs 
suggests an association or another opportunistic infection such as cytomegalovirosis, 
cryptococcosis, toxoplasmosis, or tuberculosis.  
In the third situation the clinical feature is that of bacterial pneumonia or sepsis with ARDS. 
The pathogens responsible are usuallyStreptococcus pneumoniae or Haemophilus influenzae 
and, to a lesser degree, Legionella spp.  
The fourth situation with rapid to moderate progression of the condition, fever, nodules or 
round infiltrates evolving towards dissemination and/or cavitation is highly suggestive of 
fungal pneumonia. However, legionellosis, tuberculosis and even pulmonary infarction or 
specific localisation of vasculitis may also result in similar manifestations.  
 
Immunodeficiency 
 
184 
The last situation is certainly the most complex. The clinician is confronted with focal 
pulmonary infiltrates which do not respond to antibiotics. Opportunistic agents such as 
Mycobacteria spp, Nocardia spp, or Rhodococcus equi, organising pneumonia or tumour may 
be the cause.  
5. Skin in immunocompromised 
Skin, once thought to be an inert structure, plays a vital role in protecting the individual 
from the external environment. The epidermis impedes penetration of microbial organisms, 
chemical irritation, and toxins, absorbs and blocks solar and ionized radiation, and inhibits 
water loss. 
The stratum corneum, the outermost layer of the epidermis that results from the terminal 
differentiation of the keratinocytes, forms the primary layer of protection from the external 
environment. This layer of anucleated keratinocytes is composed of highly cross-linked 
proteinaceous cellular envelopes with extracellular lipid lamellae consisting of ceramides, 
free fatty acids, and cholesterol. The free fatty acids create an acidic environment that 
inhibits colonization by certain bacteria such as Staphylococcus aureus, providing further 
protection.  
Apart from the physical barriers the skin also contain other innate immunomodulating 
substances and cells. This include cathelicidins, cytokines. neuropeptides, eicosanoids, 
reactive oxygen species and langhern cell which has phagocytic properties, and act as 
antigen presenting cell. The skin is consistently exposed to host of injuries because of their 
size and exposure to the environment. These coordinated protective barriers, cells and 
substances maintain the integrity of the skin.  
In immunodeficiency state there is alteration in this innate immune state in the skin. This 
thus predisposes the skin to many injuries – infectious and non infectious. Dermatological 
manifestations are important healthcare concerns in patients with immunodeficiency state. 
About 25% of patients with immunodeficiency had been reported with dermatological 
injuries. 
Subsequent invasion of the skin by various bacterial, viral, fungal, and parasitic agents spur 
infectious skin lesions, whereas non-infectious skin conditions mainly emerge from adverse 
drug reactions or certain inflammatory or malignant aetiologies. Thus microbial infections, 
inflammatory conditions, and neoplasms are the three main causes for the development of 
dermatological findings in immunocompromised patients. 
There have been several reports detailing the high frequency of dermatological 
manifestations in HIV infected patients, 96% in India, 70% in Taiwan, 65.3% in France, 65.3% 
in Tanzania, 34% in Thailand, 32.6% in Iran. The dermatological manifestations in these 
patients may be as a result of primary dermatological infection, metastastic infection with 
primary in another organ or systemic infection.  
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There are many organisms that are associated with infection of or manifestations in the skin 
in patients with immunodeficiency. The infections could be as a result of conventional or 
opportunistic infection. These infections include viral, bacterial, fungal and parasitic. The 
organisms that have been associated with dermatological infections or manifestation in 
immunocompromised patients are herpes simplex virus, varicella zoster virus, 
cytomegalovirus and pappiloma virus, staphylococcus spp, streptococcus spp, 
pseudomonas spp, atypical mycobacterium spp, the fungal infections including malasezia 
furfur, candidiasis, norcadia spp, Cryptococcus neoformans, Aspergillus species, 
Paecilomyces, Rhizopus species, Candida tropicalis, and scabies. 
The commonly reported dermatological lesions in immunocompromised patients include 
dermatitis, seborrheic dermatitis, folliculitis, dermatophytes including pityriasis versicolor, 
wart, Kaposi sarcoma, herpes zoster, acne vulgaris, urticaria, pruritus, psoriasis, malasma 
and erythema multiforme. Other Skin lesions including pustules, gangrenous cellulitis, 
erythematous subcutaneous nodules, hemorrhagic bullae, petechiae, ecchymoses, and 
ecthyma gangrenosum had also been reported in immunocompromised patients.  
Cutaneous manifestations often are accompanied by fever, defined as an isolated 
temperature of 38.3°C (101°F), that cannot be attributed to exogenous causes, such as blood 
products, or a temperature above 38°C (100.4°F) that persists for more than 1 hour. 
6. Central nervous system in immunocompromised 
Immune responses in the CNS are common, despite its perception as a site of immune 
privilege. These responses can be mediated by resident microglia and astrocytes, which are 
innate immune cells without direct counterparts in the periphery. Furthermore, CNS 
immune reactions often take place in virtual isolation from the innate/adaptive immune 
interplay that characterizes peripheral immunity. However, microglia and astrocytes also 
engage in significant cross-talk with CNS-infiltrating T cells and other components of the 
innate immune system. 
Microglia are key players of the immune response in the central nervous system (CNS) and 
being the resident innate immune cells, they are responsible for the early control of 
infections and for the recruitment of cells of the adaptive immune system required for 
pathogen clearance. The innate and adaptive immune responses triggered by microglia 
include the release of proinflammatory mediators. Although an efficient immune response 
is required for the defense against invading pathogens, an inflammatory response in the 
CNS may also lead to tissue injury and neurodegeneration. Engagement of Toll-like 
receptors (TLRs), a major family of pattern recognition receptors that mediate innate 
immunity but also link with the adaptive immune response, provides an important 
mechanism by which microglia are able to sense both pathogen and host derived ligands 
within the CNS. 
Patients with immunodeficiency are at risk of a wide range of neurologic diseases including 
infections, neoplasms, and drug-related complications of therapy  
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CNS infections caused by infective agents are rare in immunocompetent host, but more 
frequent in immunocompromised patients. The spectrum of causative organisms may vary 
greatly, depending on the underlying malignancy, its treatment and various other factors. 
Infections that had been reported to cause neurological diseases in immunocompromised 
patients are as detailed below;  
Viral – herpes simplex virus, JC virus, cytomegalovirus, varicella zoster virus.  
Bacterial – staphylococcus spp, pneumococcus, haemophilus spp, mycobacterium 
tuberculosis, mycobacterium Avium/ Intracellulare Complex, Listeria spp, norcadia spp. 
fungal – Cryptococcus neoformans, Aspergillus fumigatus, Zygomycetes (Mucor and Rhizopus), 
Candida albicans, Coccidioides spp 
Parasitic - toxoplasmosis, strongyloides. 
Development of neurologic manifestations depends on a variety of factors, including 
therapy with drugs like antiretroviral drugs and the patient’s overall degree of 
immunosuppression. Heavily immunocompromised patients like those after allogeneic stem 
cell transplantation (SCT) or previous T cell depleting treatment regimens (e.g. with 
fludarabine or alemtuzumab) are at highest risk for cerebral infections. . The infections can 
cause global or focal cerebral dysfunction, subhemispheric impairment, spinal cord injury 
and occasionally, peripheral nerve injury.  
Thus, in the immunosuppressed patient with neurological involvement there are three inter-
related areas to consider. First, has whatever caused the immunosuppression either directly or 
indirectly affected the nervous system? Second, are such problems due to an infection of the 
nervous system? And last, are there any medical complications that might produce a 
neurological disturbance? In assessing immunosuppressed patients, the clinician must 
remember that more than one of these factors may be involved in the neurological presentation. 
Clinical presentations in these patients may include headache, signs and symptoms of 
increased intracranial pressure, and lateralizing signs appropriate to the area(s) of 
involvement. These symptoms can include behavioral, cognitive, and personality changes. 
Focal symptoms include hemiparesis, aphasia, and visual field defects. Ataxia, seizures, and 
cranial nerve palsies can also occur but are not as common.  
Meningoencephalitis is a common presentation however the classical symptoms and signs 
may be absent in these patients.. Also cerebral toxoplasmosis, cerebral lymphoma and cerebral 
vascular accident in immunocompromised patients may have similarities in their clinical 
presentations. The nature of neurological manifestation in patients with impaired immune 
state also varies with the cause and the degree of the immunosuppression. There is need for 
high index of suspicion to avoid delay or misdiagnosis that may lead to delay in intervention. 
7. Musculoskeletal system in immunocompromised 
The immune cells and mediators had been implicated in some musculoskeletal diseases. The 
bone marrow is the source of various haematological cells including the primordial immune 
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cells. The bone marrow also harbours matured and maturing immune cells. However the 
physiological activities of both innate and acquired immunity in the musculoskeletal system 
are poorly documented. 
There is increased prevalence of musculoskeletal diseases especially infections in 
immunocompromised patients. Musculoskeletal syndromes that occur in HIV-infected 
patients include manifestations of drug toxicity, reactive arthritis, Reiter's syndrome, 
infectious arthritis, and myositis. Post transplant patients have developed myopathies and 
various bony and joint disorders. Myopathy and myositis have been reported in patients 
with diabetes mellitus and some primary immune deficiency disorders. 
Some other musculoskeletal disorders in patients with immunodeficiency include some 
syndromes with arthritis or myositis as one of the components eg Reiters syndrome, 
Dermatomyositis, Sjogrens syndrome, Polyomyositis and Psoriasis.  
The hallmark of the presentation is pain in the muscle, swelling of muscle, occasionally 
associated with fever and muscle atrophy. Arthralgia, swelling of the joint and when 
intervention is delayed distortion of the joint. Patient may develop cellulitis with or without 
abscess formation and osteomyelitis. There is need for prompt diagnosis and intervention as 
delay may lead to rapid spread of the infection in these patients. 
8. Urogenital system in immunocompromised 
The urogenital tract contain both cellular and non cellular innate immune components. This 
ensure the sterility of the urinary tract and part of the genital tract. In immunodeficiency 
state the urogenital tract are exposed to higher prevalence of both common and rare 
infections. The urogenital diseases that have been reported in immunocompromised 
patients include urinary tract infection, epididymitis, prostatitis, extensive condylomata of 
the urethra, renal abscess and other renal related diseases. 
The occurrence of urinary tract infection and its clinical impact is determined, as with any 
infectious disease, by the interaction between the virulence of the infecting organism and the 
host defense mechanisms that can be mobilized. In the case of urinary tract infections, an 
anatomically and functionally intact kidney and urinary tract are the primary host defenses, 
with phagocytic function and immune mechanisms coming into play to limit the 
consequences of those infections.  
Defects in the immune system determine the clinical manifestations and severity of urinary 
tract infections (UTI) and the rates of complication. However they only have an indirect role 
in influencing susceptibility to infection. Of all the categories of immunocompromised hosts, 
the renal transplant patient is the one most susceptible to the direct and indirect 
consequences of urinary tract infections. The rates of UTI in diabetics, renal transplant, 
recipients, neutropenic patients, and patients with AIDS are primarily determined by the 
degree and duration of urinary tract manipulation, and the higher perineal prevalence of 
potential pathogens that result from frequent hospitalization and antimicrobial use. 
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Urogenital tract infection has a different clinicoradiological presentation in 
immunocompromised patients, with predominance of systemic symptoms, multiple 
parenchymatous renal foci, and lower frequency of lesions of the collecting system. In the 
context of immunosuppression, Urogenital tract infection behaves as a severe bacterial 
infection, with bacteremia and visceral metastatic foci. 
Many patients are asymptomatic. Symptoms that may occur include dysuria, urinary 
frequency and incontinence, flank pain, and fever. Confusion and delirium are often 
attributed to UTI, although without high fever or sepsis. Uncomplicated UTI is unlikely to 
cause serious central nervous dysfunction. The clinical signs and follow up of these 
infections were straight forward in half of the cases. However, in some patients, the 
infection is fulminant with progression to an abscess despite the use of antibiotics or is 
unusual because of the pathogens isolated. 
Mycobacterial agents causing UTIs are less frequent in immunocompetent individuals; they 
are more common and severe in immunocompromised individuals. Extra pulmonary 
tuberculosis (EPTB) represents a progressively greater proportion of new cases and the 
genitourinary tract is the most common site of EPTB. The most common causative organism 
of kidney and urinary tract tuberculosis is the Mycobacterium tuberculosis, and occasionally 
Mycobacterium bovis can also be responsible. Mycobacterium tuberculosis (MTB) has an 
important impact on kidney transplant recipients, particularly during the first year after 
surgery. Tuberculosis of the urinary tract is easily overlooked. Symptoms that sometimes 
occur include back, flank and suprapubic pain, hematuria, frequency, and nocturia. These 
might also suggest conventional bacterial urinary tract infection. Symptoms such as fever, 
weight loss, and night sweats also are not unusual. 
A variety of renal syndromes have been reported in patients with immunosupression. These 
can be either acute or chronic kidney disease including electrolyte abnormalities. Renal 
impairment from opportunistic infections and drugs used in these patients has also been 
reported. A broad spectrum of renal diseases affecting glomerular, tubular and interstitial 
tissues had been documented in immunocompromised patients especially HIV infected 
patients. Most of the renal manifestations represent complications of concurrent infections in 
a severely immunocompromised host, or side effects of the plethora of treatments required 
to manage these patients. The renal related presentations except for hypertension and 
oedema are consistent with clinical presentations in renal disease in immunocompetent 
patients, however severity varies with the degree of immunosuppression. Hypertension and 
oedema were reported as not common in immunocompromised patients. The renal disease 
in these patients deteriorates faster without intervention thus the need for early diagnosis 
and prompt intervention. 
9. Conclusion  
Immunocompromised patients are predisposed to a variety of clinical syndromes. The 
manifestations depend on the cause of immunosuppression, the degree of 
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immunosupression, the endemic infections, the system or organ with predominant injury, 
and other associated diseases like Malignancies and infiltrative diseases. It is noteworthy 
that these patients may have atypical presentations. Thus there is need for surveillance and 
high index of suspicion of injuries/diseases in these patients to ensure early diagnosis and 
intervention. 
Author details 
Umezurike Hughes Okafor 
Enugu State University Teaching Hospital, Parklane, Enugu, Nigeria 
10. References 
Ayaz A, Biviji MD, Guy D. et al. musculoskeletal manifestation of human immunodeficiency 
virus. Am Acad Ortho Surgeons; 10(3): 833-838 
Ana Rañó, Carlos Agustí, Natividad Benito et al. Prognostic Factors of Non-HIV 
Immunocompromised Patients with Pulmonary Infiltrates. CHEST (2002); 122 (1): 253-
261 
C Dougan, I Ormerod. A neurologist's approach to the immunosuppressed patient. J Neurol 
Neurosurg Psychiatry 2004;75:i43-i49 doi:10.1136/jnnp.2003.035071  
Dawn McGuire. Neurologic Manifestations of HIV .HIV InSite Knowledge Base Chapter 
June 2003  
Elizabeth Boskey Immunocompromised. www/ About.com (2010) 
Figueiredo AA, Lucon AM, Júnior RF, Ikejiri DS, Nahas WC, Srougi M. Urogenital 
tuberculosis in immunocompromised patients. Int Urol Nephrol. 2009;41(2):327-33. 
Epub 2008 Jul 22. 
Foroughi et al. Prevalence of dermatologic manifestations among people living with 
HIV/AIDS in Imam Khomeini Hospital in Tehran, Iran. Journal of AIDS and HIV 
Research Vol. 4(2), pp. 56-59, February 2012 
Fred A. Lopez, Charles V. Sanders. Recognizing Cutaneous Signs of Infection in 
Immunocompromised Patients. Hematol Oncol. 2003;6(3): 1 – 4 
Immune Deficiency Foundation. Primary Immunodeficiency Diseases. Family Handbook; 
Baxter. Fourth Edition. 2007 : Chapter XI. 
J. Harold Helderman, Simin G. Gastrointestinal complications of transplant 
immunosuppression. J Am Soc Nephrol 13: 277–287, 2002 
Javier Munoz, Philip Kuriakose. Rash in an Immunocompromised Patient. JAMA. 
(2012);307(6):612-613. . 
Kahn LH.  The growing number of immunocompromised. Bulletin of the Atomic Scientists 
(2008): www/thebulletin.org 
Nancy Lane. Rheumatologic and musculoskeletal manifestation of HIV. HIV inSite 
Knowledge Base chapter 1998. 
Nick Murphy, Tony Whitehouse, Mark Cook. Immunocompromised; PACT (2010): 1 –57 
 
Immunodeficiency 
 
190 
Ping Zhang, Gregory J. Bagby, Kyle I. Happel, Caroline E. Raasch, Steve Nelson. Alcohol 
Abuse, Immunosuppression, and Pulmonary Infection Current Drug Abuse Reviews, 
2008, Vol. 1, No. 1 
Ranjan K , Sharma M . An Approach to the Detection of Mycobacteria in Clinically 
Suspected Cases of Urinary Tract Infection in Immunocompromised Patients . 
WebmedCentral. Bacteriology 2010;1(9):WMC00616 
Tolkoff-Rubin NE, Rubin RH. Urinary tract infection in the immunocompromised host. 
Lessons from kidney transplantation and the AIDS epidemic. Infect Dis Clin North Am. 
1997 Sep;11(3):707-17. 
Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infections in 
immunocompromised patients. Medicine (Baltimore). 1985 Mar;64(2):115-33 
